RecruitMe Clinical Trial

A Multicenter, Open-label, Pilot Study of TAK-935 in patients with 15q duplication syndrom or CDKL5 deficiency disorder.
A clinical trial for children with 15Q duplication syndrome or CDKL5 deficiency disorder to help control seizures.
Sponsor:Ovid Therapeutics, Inc.
Enrolling:Male and Female Patients
Study Length:22 Weeks
Clinic Visits:8
Age Range:Between 2 and 17 years old
IRB Number:AAAS1026
U.S. Government ID:NCT03694275
Contact: Joanne Carroll: 212-305-5508 / jc688@cumc.columbia.edu
Additional Study Information:

The purpose of this research is to determine whether a new investigational drug called TAK-935 is safe and whether it may help treat epilepsy in children with 15q duplication syndrome or CDKL5 deficiency disorder.

Do You Qualify?
Has your child been diagnosed with 15q duplication syndrome, or CDKL5 deficiency disorder?YesNo
Has your child had 3 or more seizures within the last 3 months?YesNo
Have there been any anti-epileptic medication changes within the last 4 weeks?YesNo
Does your child weigh 22 lbs or more?YesNo
Submit
Cancel
Investigator
Wendy Chung, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Joanne Carroll
Email: jc688@cumc.columbia.edu
Phone: 212-305-5508